114 related articles for article (PubMed ID: 23298964)
1. Lipid metabolism.
Sattar N
Curr Opin Lipidol; 2013 Feb; 24(1):101-2. PubMed ID: 23298964
[No Abstract] [Full Text] [Related]
2. Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox.
González-Gay MA; González-Juanatey C
Ann Rheum Dis; 2014 Jul; 73(7):1281-3. PubMed ID: 24907362
[No Abstract] [Full Text] [Related]
3. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
[TBL] [Abstract][Full Text] [Related]
4. [Cardiovascular risk in systemic inflammatory diseases].
Marsico F; Parente A; Paolillo S; Casaretti L; Lo Iudice F; Pirozzi E; Conte S; Iardino E; Gambardella F; Della Ratta GL; Cirillo A; Vitagliano A; Filardi PP
G Ital Cardiol (Rome); 2013; 14(7-8):517-25. PubMed ID: 23877549
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
Popa C; van Tits LJ; Barrera P; Lemmers HL; van den Hoogen FH; van Riel PL; Radstake TR; Netea MG; Roest M; Stalenhoef AF
Ann Rheum Dis; 2009 Jun; 68(6):868-72. PubMed ID: 18635596
[TBL] [Abstract][Full Text] [Related]
6. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions.
Choy E; Sattar N
Ann Rheum Dis; 2009 Apr; 68(4):460-9. PubMed ID: 19286905
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-α inhibitor use is not associated with lipid changes in rheumatoid arthritis.
Bili A; Morris SJ; Sartorius JA; Kirchner HL; Antohe JL; Dancea S; Wasko MC
J Rheumatol; 2012 May; 39(5):946-8. PubMed ID: 22467937
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
Avouac J; Allanore Y
Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
[TBL] [Abstract][Full Text] [Related]
9. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.
Dahlqvist SR; Engstrand S; Berglin E; Johnson O
Scand J Rheumatol; 2006; 35(2):107-11. PubMed ID: 16641043
[TBL] [Abstract][Full Text] [Related]
10. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors.
Egnatios G; Warthan MM; Pariser R; Hood AF
J Drugs Dermatol; 2008 Oct; 7(10):975-7. PubMed ID: 19112764
[No Abstract] [Full Text] [Related]
11. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis.
Dessein PH; Joffe BI; Stanwix AE
J Rheumatol; 2003 Jul; 30(7):1403-5. PubMed ID: 12858433
[No Abstract] [Full Text] [Related]
12. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
Kaplan MJ
Nat Clin Pract Rheumatol; 2005 Dec; 1(2):74-5. PubMed ID: 16932633
[No Abstract] [Full Text] [Related]
13. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
Popa C; van den Hoogen FH; Radstake TR; Netea MG; Eijsbouts AE; den Heijer M; van der Meer JW; van Riel PL; Stalenhoef AF; Barrera P
Ann Rheum Dis; 2007 Nov; 66(11):1503-7. PubMed ID: 17472994
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk factors in inflammatory arthritis.
Mirjafari H; Al-Husain A; Bruce IN
Curr Opin Lipidol; 2011 Aug; 22(4):296-301. PubMed ID: 21670670
[TBL] [Abstract][Full Text] [Related]
15. Atypical mycobacteria: showerheads, anti-TNF therapy and Crohn's disease.
Desai AA; Marks DJ
Expert Rev Clin Immunol; 2010 Sep; 6(5):695-9. PubMed ID: 20828275
[No Abstract] [Full Text] [Related]
16. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
Spanakis E; Sidiropoulos P; Papadakis J; Ganotakis E; Katsikas G; Karvounaris S; Bizaki A; Kritikos H; Boumpas DT
J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
[TBL] [Abstract][Full Text] [Related]
17. Lipid profiles in untreated patients with rheumatoid arthritis.
Park YB; Lee SK; Lee WK; Suh CH; Lee CW; Lee CH; Song CH; Lee J
J Rheumatol; 1999 Aug; 26(8):1701-4. PubMed ID: 10451065
[TBL] [Abstract][Full Text] [Related]
18. Novel insights into anti-inflammatory actions of HDL.
van Wijk DF; Stroes ES; Dallinga-Thie GM
Atherosclerosis; 2010 Oct; 212(2):388-9. PubMed ID: 20650459
[No Abstract] [Full Text] [Related]
19. Cardiovascular events and survival in rheumatoid arthritis: effects of anti-tumor necrosis factor-alpha treatment.
Cugno M
Transl Res; 2011 Jan; 157(1):6-9. PubMed ID: 21146145
[No Abstract] [Full Text] [Related]
20. [Rheumatoid arthritis: a cardiovascular disease?].
Daïen CI; Fesler P
Ann Cardiol Angeiol (Paris); 2012 Apr; 61(2):111-7. PubMed ID: 21885031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
